ClinicalTrials.gg
CompletedNCT02731469Updated Jul 1, 2019Results posted

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

A Phase 1 interventional study of BCD-131 and Mircera® in Reticulocyte Count, sponsored by Biocad. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-01.

Sponsored by Biocad · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

BCD-131-1 is an Open-Label Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, Safety and Immunogenicity of Single Ascending Doses of BCD-131 in Healthy Volunteers

Read the detailed description

BCD-131 is novel drug product of pegylated darbepoetin alfa.

Clinical trial BCD-131-1 will be conducted in two stages:

Stage I is an open-label, non-randomized clinical study of pharmacokinetics, pharmacodynamics, tolerability, safety and immunogenicity of BCD-131 given to healthy volunteers at ascending doses (Phase 1, a traditional "3+3" design).

Also, the PK and PD parameters of the closest analogues of BCD-131 (Mircera and Aranesp) given as subcutaneous injections at therapeutic doses will be evaluated.

Stage II aims to further evaluate pharmacokinetics, pharmacodynamics and safety of subcutaneous and intravenous injections of BCD-131 at a dose which ensures PD effects similar to those of the closest analogues (Mircera, Aranesp) given as subcutaneous injections at therapeutic doses.

02

Conditions studied

  • Reticulocyte Count
03

In context

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signing of the Form;
  2. Male sex;
  3. Age of 18 to 45 years, inclusive;
  4. within normal limits (18.5-24.9 kg/m2);
  5. Healthy patients, which is proved by their medical history, physical examination and laboratory findings:

    • No abnormalities of circulatory, respiratory, nervous, hematopoietic, endocrine and digestive systems, liver and kidneys in the past medical history and at screening;
    • No history of cardiovascular disorders or thyroid disorders;
    • No history of hematologic disorders, including but not limited to any type of anemia, myelodysplastic syndrome, blood cancers, hemolytic syndrome, hemoglobinopathies, coagulopathies;
    • CBC results within normal limits, including:

      • within 132-173 g/L;
      • Hematocrit (based on CBC results) within 39-49%;
      • count within 150-400*109/L;
      • Absolute reticulocyte count within 30.4-93.5 * 109/L;
    • Blood biochemistry and urinalysis results within normal limits;
    • Serum ferritin within 20-250 µg/L;
    • Serum endogenous erythropoietin within 4.3-29.0 MIU/mL;
    • Hemodynamic parameters within normal limits: systolic blood pressure within 100-139 mmHg; diastolic blood pressure within 60-90 mmHg; heart rate within 50-90 bpm;
    • No history of chronic infections (tuberculosis) or chronic inflammation;
    • No or C, , or syphilis;
    • No acute infections within 4 weeks prior to inclusion in the study;
    • No psychiatric disorders and other conditions (including depression) that can interfere with the volunteer's ability to follow the study protocol;
    • Well-being (in the volunteer's opinion) within 30 days prior to inclusion in the study;
  6. No history of or current (at baseline) alcohol or drug abuse;
  7. Ability of the volunteer, in the investigator's opinion, to follow the study protocol procedures;
  8. Willingness of volunteers and their sexual partners with preserved to use reliable within 2 weeks before inclusion in the study and up to 7 weeks after the injection of the test product. This criterion is not applicable to subjects who underwent surgical sterilization. Reliable methods of contraception include one barrier method in combination with one of the following methods: spermicides, intrauterine device/oral contraceptives (for sexual partners).
  9. Willingness of volunteers to avoid alcohol intake within 24 hours before and 8 days after each injection of the test drug;

Exclusion criteria

Exclusion Criteria:

  1. History of treatment with erythropoietins or any other ESAs;
  2. Acute bleeding, blood/plasma donation or blood transfusion within 2 months before inclusion in the study;
  3. History of chronic bleeding;
  4. Standard laboratory and instrumental findings outside normal limits at screening;
  5. History of allergies (anaphylactic shock or multiple drug allergy syndrome);
  6. Known allergy or intolerance to any components of the product;
  7. Major surgery within 30 days prior to screening, or surgery being scheduled for any time during the study;
  8. Impossibility to install a venous catheter for blood sampling (e.g. because of skin disorders at the sites of venipuncture);
  9. Diseases or other conditions that can interfere with the pharmacokinetics of the investigational drug (e.g. chronic liver, kidney, blood, circulatory system, lung or neuroendocrine diseases, including diabetes mellitus and others);
  10. History of fever of 40 °C or more;
  11. History of elevated hepatic transaminases (above 2.5xULN);
  12. Episodes of thrombosis and/or thromboembolia in past medical history (myocardial infarction, stroke, , deep vein thrombosis, pulmonary embolism within 6 months prior to inclusion in the study) as well as an increased risk of deep vein thrombosis;
  13. History of epileptic attacks or seizures;
  14. History or current (at screening) depression, suicidal thoughts/ attempts;
  15. Regular oral or parenteral use of any medications including over-the-counter drugs, vitamins and nutritional additives within 2 weeks before a scheduled injection of the test drug;
  16. Use of drugs, including OTC products, that significantly affect the hemodynamics, hepatic function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days before a scheduled injection of the test drug;
  17. Vaccination within 4 weeks before a scheduled injection of the test drug;
  18. Smoking more than 10 cigarettes per day;
  19. Consumption of more than 10 portions of alcohol per week (one portion equals to 0.5 L of beer, 200 mL of wine or 50 mL of ethanol) or a history of alcohol, drug or medication abuse;
  20. Participation in other clinical studies within 1 month before screening or simultaneous participation in another clinical study;
  21. Previous participation in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    BCD-131, 0.05 mcg/kg subcutaneously

    Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously

    Biological: BCD-131

  • Experimental
    BCD-131, 0.15 mcg/kg subcutaneously

    Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously

    Biological: BCD-131

  • Experimental
    BCD-131, 0.40 mcg/kg subcutaneously

    Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously

    Biological: BCD-131

  • Experimental
    BCD-131, 1.05 mcg/kg subcutaneously

    Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously

    Biological: BCD-131

  • Experimental
    BCD-131, 1.70 mcg/kg SC

    Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously

    Biological: BCD-131

  • Experimental
    BCD-131, 2.25 mcg/kg SC

    Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously

    Biological: BCD-131

  • Experimental
    BCD-131, 4.45 mcg/kg subcutaneously

    Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously

    Biological: BCD-131

  • Active comparator
    Mircera®, 1.20 mcg/kg subcutaneously

    Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously

    Biological: Mircera®

  • Active comparator
    Aranesp®, 0.45 mcg/kg subcutaneously

    Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously

    Biological: Aranesp®

  • Experimental
    BCD-131, optimal dose, intravenously

    Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously

    Biological: BCD-131

  • Experimental
    BCD-131, optimal dose, subcutaneously

    Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously

    Biological: BCD-131

Interventions

  • BiologicalBCD-131

    Also known as: pegylated darbepoetin alfa

  • BiologicalMircera®

    Also known as: Methoxy polyethylene glycol-epoetin beta

  • BiologicalAranesp®

    Also known as: darbepoetin alfa

06

What researchers measure

Primary outcomes

  1. AUC (0-1176 Hours)

    Area under curve (AUC) "concentration - time" from 0 hours to 1176 hours and to infinity

    Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 h post dose

Secondary outcomes

  1. Cmax

    Maximal concentration of drug in blood after single injection

    Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose

  2. Tmax

    Time from 9 hours to time of maximal concentration of drug in blood after single injection

    Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose

  3. T1/2

    Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible

    Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose

  4. Kel

    Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible

    Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose

  5. Clearance of BCD-131

    Clearance of BCD-131 in blood after single injection

    Time frame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose

  6. AUEC (0-1176 Hours) - Reticulocytes

    Area under effect curve (AUEC) "absolute reticulocyte count - time" from 0 to 1176 hours post-dose after single injection of study drug

    Time frame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose

  7. AUEC (0-1176 Hours) - Hemoglobin

    Area under effect curve (AUEC) "hemoglobin - time" from 0 to 1176 hours post-dose after single injection of study drug

    Time frame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose

  8. AC-Emax - Reticulocytes

    Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug

    Time frame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose

  9. AC-Emax - Hemoglobin

    Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug

    Time frame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose

  10. Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale

    visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome

    Time frame: intraoperative

  11. Number of Participants With Adverse Events and Serious Adverse Events

    Total incidence of adverse events (AE)/ serious adverse events (SAE)

    Time frame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)

  12. Number of Participants With Local Reactions

    Incidence of administration site reactions

    Time frame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)

  13. Number of Participants With AE/SAE 3-4 Grade CTCAE

    Incidence of Grade 3-4 AEs and SAEs.

    Time frame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)

  14. Number of Participants With Early Withdrawal Due to AE

    Frequency of early withdrawals due to AEs and SAEs

    Time frame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)

  15. Number of Participants With Binding Antibodies to BCD-131

    Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131

    Time frame: 0, day 50 post-dose

07

Results

Posted Jul 1, 2019

Participant flow

Participant flow — Overall Study
MilestoneBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Started33333336666
Completed33333336666
Not completed00000000000

Outcome measures

PrimaryAUC (0-1176 Hours)

Area under curve (AUC) "concentration - time" from 0 hours to 1176 hours and to infinity

Time frame:
0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 h post dose
Reported as:
Median · pg*hr/ml
AUC (0-1176 Hours)
pg*hr/mlBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
AUC (0-1176 Hours)206974.500 (144988.500 to 485443.500)657417.000 (598401.500 to 666088.500)827904.750 (362302.000 to 1179816.500)1360020.000 (424094.000 to 1427990.750)1314197.750 (64430.000 to 1465335.500)3202606.500 (2173496.250 to 4300376.000)5220198.750 (4658082.250 to 5328878.250)688124.000 (478496.000 to 1252376.250)94628.375 (49807.250 to 113412.500)6382389.188 (4818041.5 to 6826251.75)2089193.125 (789943 to 2926898)
SecondaryCmax

Maximal concentration of drug in blood after single injection

Time frame:
0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
Reported as:
Median · picogram per ml
Cmax
picogram per mlBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Cmax585.000 (503.000 to 744.000)1035.000 (854.000 to 1761.000)2248.000 (1457.000 to 2566.000)3634.000 (2924.000 to 4954.000)3541.000 (150.000 to 4110.000)12023.000 (6863.000 to 12243.000)15433.000 (13286.000 to 16404.000)2298.000 (1849.000 to 6867.000)964.500 (870.000 to 1229.000)87526.5 (69859 to 93090)10588 (3713 to 11692)
SecondaryTmax

Time from 9 hours to time of maximal concentration of drug in blood after single injection

Time frame:
0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
Reported as:
Median · hours
Tmax
hoursBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Tmax216.000 (96.000 to 504.000)168.000 (72.000 to 504.000)96.000 (8.000 to 96.000)72.000 (48.000 to 72.000)72.000 (48.000 to 168.000)120.000 (96.000 to 168.000)96.000 (72.000 to 96.000)48.000 (48.000 to 72.000)36.000 (8.000 to 36.000)0.75 (0.5 to 1)84 (72 to 96)
SecondaryT1/2

Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible

Time frame:
0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
Reported as:
Median · hours
T1/2
hoursBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
T1/2322.094 (322.094 to 322.094)—377.272 (281.082 to 473.461)212.231 (212.231 to 212.231)416.482 (326.648 to 506.316)191.477 (145.071 to 495.813)181.310 (168.649 to 186.681)114.855 (105.888 to 256.031)79.473 (44.619 to 104.605)116.125 (70.7 to 120.38)182.392 (123.71 to 197.76)
SecondaryKel

Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible

Time frame:
0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
Reported as:
Median · fraction per hour
Kel
fraction per hourBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Kel0.002152 (0.002152 to 0.002152)—0.001965 (0.001464 to 0.002466)0.003266 (0.003266 to 0.003266)0.001746 (0.001369 to 0.002122)0.003620 (0.001398 to 0.004778)0.003823 (0.003713 to 0.004110)0.006057 (0.003734 to 0.006549)0.009019 (0.006697 to 0.019655)0.005977 (0.003424 to 0.006196)0.003828 (0.001367 to 0.00415)
SecondaryClearance of BCD-131

Clearance of BCD-131 in blood after single injection

Time frame:
0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
Reported as:
Median · ml per hour
Clearance of BCD-131
ml per hourBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Clearance of BCD-13117.393 (8.446 to 24.140)16.200 (15.313 to 21.808)33.337 (24.411 to 83.908)54.043 (48.530 to 225.304)92.812 (91.843 to 1820.580)65.259 (46.682 to 88.567)51.774 (51.147 to 57.320)108.993 (59.886 to 156.741)332.263 (304.017 to 602.322)29.84 (24.293 to 30.734)136.391 (48.481 to 202.399)
SecondaryAUEC (0-1176 Hours) - Reticulocytes

Area under effect curve (AUEC) "absolute reticulocyte count - time" from 0 to 1176 hours post-dose after single injection of study drug

Time frame:
0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
Reported as:
Median · cells (10^9) * hr/l
AUEC (0-1176 Hours) - Reticulocytes
cells (10^9) * hr/lBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
AUEC (0-1176 Hours) - Reticulocytes10568.04 (10107.60 to 10940.76)348.000 (144.000 to 1980.000)2868.000 (2664.000 to 17556.00)11004.00 (6006.000 to 13416.00)14481.60 (10366.80 to 15530.40)25512.00 (16476.00 to 30355.20)69120.00 (46183.20 to 81511.20)10269.72 (3121.200 to 16310.88)14223.60 (8736.000 to 21257.28)21370.44 (18081.6 to 22724.88)13129.2 (4432.56 to 15072)
SecondaryAUEC (0-1176 Hours) - Hemoglobin

Area under effect curve (AUEC) "hemoglobin - time" from 0 to 1176 hours post-dose after single injection of study drug

Time frame:
0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
Reported as:
Median · gr*hr/l
AUEC (0-1176 Hours) - Hemoglobin
gr*hr/lBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
AUEC (0-1176 Hours) - Hemoglobin864.00 (528.00 to 2460.00)216.00 (0.00 to 1260.00)1992.00 (1152.00 to 3864.00)4752.00 (2688.00 to 6924.00)1548.00 (1320.00 to 10128.00)1392.00 (660.00 to 23460.00)3516.00 (2904.00 to 4248.00)3492.00 (720.00 to 6156.00)3120.00 (2112.00 to 4320.00)4008 (2340 to 4044)4632 (2448 to 4812)
SecondaryAC-Emax - Reticulocytes

Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug

Time frame:
0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
Reported as:
Median · 10e9 reticulocytes per liter"
AC-Emax - Reticulocytes
10e9 reticulocytes per liter"BCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
AC-Emax - Reticulocytes23.65 (17.15 to 31.34)6.00 (6.00 to 22.00)13.00 (11.00 to 34.00)27.00 (12.00 to 28.00)20.68 (17.00 to 26.00)112.00 (81.00 to 132.00)110.00 (69.00 to 171.00)58.00 (48.00 to 91.42)62.22 (48.00 to 153.10)70.18 (67 to 72.76)57.5 (45.4 to 58)
SecondaryAC-Emax - Hemoglobin

Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug

Time frame:
0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
Reported as:
Median · gramm per liter
AC-Emax - Hemoglobin
gramm per literBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
AC-Emax - Hemoglobin8.00 (3.00 to 11.00)2.00 (0.00 to 22.00)7.00 (5.00 to 9.00)9.00 (8.00 to 15.00)9.00 (6.00 to 21.00)6.00 (4.00 to 26.00)10.00 (8.00 to 10.00)10.50 (3.00 to 12.00)9.00 (8.00 to 13.00)11.00 (8.00 to 13.00)10.5 (9.00 to 12.00)
SecondaryIntensity of Pain After Subcutaneous Injection According to Visual Analog Scale

visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome

Time frame:
intraoperative
Reported as:
Median · score on a scale
Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale
score on a scaleBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale0 (0 to 2)0 (0 to 0)0 (0 to 2)2 (0 to 2)2 (0 to 2)0 (0 to 2)2 (0 to 2)0 (0 to 0)2 (0 to 2)——
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events

Total incidence of adverse events (AE)/ serious adverse events (SAE)

Time frame:
from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events
ParticipantsBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Number of Participants With Adverse Events and Serious Adverse Events01220024445
SecondaryNumber of Participants With Local Reactions

Incidence of administration site reactions

Time frame:
from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
Reported as:
Count of participants · Participants
Number of Participants With Local Reactions
ParticipantsBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Number of Participants With Local Reactions00000000000
SecondaryNumber of Participants With AE/SAE 3-4 Grade CTCAE

Incidence of Grade 3-4 AEs and SAEs.

Time frame:
from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
Reported as:
Count of participants · Participants
Number of Participants With AE/SAE 3-4 Grade CTCAE
ParticipantsBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Number of Participants With AE/SAE 3-4 Grade CTCAE00000000100
SecondaryNumber of Participants With Early Withdrawal Due to AE

Frequency of early withdrawals due to AEs and SAEs

Time frame:
from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
Reported as:
Count of participants · Participants
Number of Participants With Early Withdrawal Due to AE
ParticipantsBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Number of Participants With Early Withdrawal Due to AE00000000000
SecondaryNumber of Participants With Binding Antibodies to BCD-131

Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131

Time frame:
0, day 50 post-dose
Reported as:
Count of participants · Participants
Number of Participants With Binding Antibodies to BCD-131
ParticipantsBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Number of Participants With Binding Antibodies to BCD-13100000000000

Adverse events

Collected over from the first administration of the first dose of the drug up to the end of follow up period (28 days after the last administration of the drug). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCD-131, 0.05 mcg/kg Subcutaneously0/3 (0%)0/3 (0%)0/3 (0%)
BCD-131, 0.15 mcg/kg Subcutaneously0/3 (0%)0/3 (0%)1/3 (33.3%)
BCD-131, 0.40 mcg/kg Subcutaneously0/3 (0%)0/3 (0%)2/3 (66.7%)
BCD-131, 1.05 mcg/kg Subcutaneously0/3 (0%)0/3 (0%)2/3 (66.7%)
BCD-131, 1.70 mcg/kg SC0/3 (0%)0/3 (0%)0/3 (0%)
BCD-131, 2.25 mcg/kg SC0/3 (0%)0/3 (0%)0/3 (0%)
BCD-131, 4.45 mcg/kg Subcutaneously0/3 (0%)0/3 (0%)2/3 (66.7%)
Mircera®, 1.20 mcg/kg Subcutaneously0/6 (0%)0/6 (0%)4/6 (66.7%)
Aranesp®, 0.45 mcg/kg Subcutaneously0/6 (0%)0/6 (0%)4/6 (66.7%)
BCD-131, Optimal Dose, Intravenously0/6 (0%)0/6 (0%)4/6 (66.7%)
BCD-131, Optimal Dose, Subcutaneously0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent other events
Most frequent other events
EventBCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, Subcutaneously
Platelet count increasedBlood and lymphatic system disorders0/30/30/32/30/30/30/30/60/61/60/6
eosinophils increasedBlood and lymphatic system disorders0/30/30/30/30/30/30/34/60/60/60/6
Neutrophiles decreasedBlood and lymphatic system disorders0/30/30/30/30/30/30/30/60/61/63/6
platelet count decreasedBlood and lymphatic system disorders0/31/30/30/30/30/30/30/60/60/60/6
monocytes count decreasedBlood and lymphatic system disorders0/30/31/30/30/30/30/30/60/60/60/6
basophils increasedBlood and lymphatic system disorders0/30/31/30/30/30/30/30/62/60/60/6
Blood bilirubin increasedHepatobiliary disorders0/30/30/30/30/30/31/30/62/62/60/6
AST increasedBlood and lymphatic system disorders0/30/30/30/30/30/31/30/60/60/60/6
Leucocytes decreasedBlood and lymphatic system disorders0/30/30/30/30/30/30/30/60/60/61/6
HypoglycemiaBlood and lymphatic system disorders0/30/30/30/30/30/30/30/60/60/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)BCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, SubcutaneouslyTotal
Median24 (21 to 25)26 (22 to 36)30 (23 to 40)32 (23 to 36)26 (26 to 27)25 (22 to 32)25 (22 to 26)28 (22 to 31)28 (25 to 31)24 (23 to 29)25 (25 to 27)26 (23 to 30)
Sex: Female, Male
Sex: Female, Male(Participants)BCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, SubcutaneouslyTotal
Female000000000000
Male3333333666645
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BCD-131, 0.05 mcg/kg SubcutaneouslyBCD-131, 0.15 mcg/kg SubcutaneouslyBCD-131, 0.40 mcg/kg SubcutaneouslyBCD-131, 1.05 mcg/kg SubcutaneouslyBCD-131, 1.70 mcg/kg SCBCD-131, 2.25 mcg/kg SCBCD-131, 4.45 mcg/kg SubcutaneouslyMircera®, 1.20 mcg/kg SubcutaneouslyAranesp®, 0.45 mcg/kg SubcutaneouslyBCD-131, Optimal Dose, IntravenouslyBCD-131, Optimal Dose, SubcutaneouslyTotal
American Indian or Alaska Native000000000000
Asian000000000000
Native Hawaiian or Other Pacific Islander000000000000
Black or African American000000000000
White3333333666645
More than one race000000000000
Unknown or Not Reported000000000000
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Mar 2017, 9 months.

Results were first posted in Jul 2019, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2016
First posted
Apr 7, 2016
StartActual
Jun 15, 2016
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Results first posted
Jul 1, 2019
Last update
Jul 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02731469
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Apr 7, 2016
Start date
Jun 15, 2016
Primary completion
Mar 2017
Completion
Mar 2017
Results posted
Jul 1, 2019
Last update
Jul 1, 2019

Study contacts

Roman Ivanov, PhD
study chair · JCS BIOCAD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion